Dr Laith Al-Rubaiy is a London based Consultant Gastroenterologist & Hepatologist. He is a clinical academic consultant and qualified in managing all aspects of gastroenterology and liver conditions.
Alcoholic liver disease, Problems with the Pancreas and malabsorption, Irritable Bowel Disease, Inflmmatory Bowel disease, Acid reflux , gastritis, gastric or duodenal ulcer disease, Fatty liver disease, Diverticular bowel disease, viral hepatitis, Autoimmune liver disease, Liver cirrhosis, Chronic liver disease ,Endoscopy and Colonoscopy.
Dr Laith Al-Rubaiy’s clinical work is based at St Mark’s hospital. He manages patients with various liver and bile ducts problems and other gastroenterology problems such as Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), diarrhoea, weight loss, anaemia and acid reflux disease. He performs and trains upper and lower gastrointestinal endoscopy to investigate these conditions.
1. PhD in developing patients reported outcome measures to support the care of patients in gastroenterology.
2. European Board certified in Gastroenterology and Hepatology
3. Advanced hepatology and liver transplant training at the Royal Free Hospital in London
4. Fellowship of the Royal College of Physicians in London
Dr Al-Rubaiy is an award winning doctor. He has been awarded 3 competitive national and local awards for my work in Gastroenterology and Hepatology. He has also been awarded 12 funding grants and 2 highly competitive scholarships throughout his career in the USA and UK. His current research is focused on developing and applying patients reported outcomes measures (PROMs) in Hepatology and Gastroenterology. He is a reviewer for a number of international journals and grant funding bodies and an author on several peer-reviewed publications. Some of his latest publications are:
1. Benmassaoud A, Alrubaiy L, et al . A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia. Aliment Pharmacol Ther. 2019 Nov;50(9):1049-1058.
2. Alrubaiy L, et al. PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis. Aliment Pharmacol Ther. 2019 Dec;50(11-12):1223-1231.
3. Clement C, Rapport F, Seagrove A, Alrubaiy L, Williams J. Healthcare professionals’ views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial. BMJ Open. 2017 Feb 22;7(2):e014512. doi: 10.1136/bmjopen-2016-014512.
4. Alrubaiy L, et al Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open. 2013 Jul 9;3(7). pii: e003192. doi: 10.1136/bmjopen-2013-003192. Print 2013. PubMed PMID: 23842503;
5. Williams JG, Alam MF, Alrubaiy L, et al. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technol Assess. 2016 Jun;20(44):1-320. doi: 10.3310/hta20440.
6. Hutchings HA, Cheung WY, Alrubaiy L, et al. Development and validation of the Gastrointestinal Endoscopy Satisfaction Questionnaire (GESQ). Endoscopy. 2015 Dec;47(12):1137-43.
